Alternative Sedation During Bronchoscopy

NCT01158820

Last updated date
Study Location
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Sedation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-90 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adults over the age of 18 scheduled for elective flexible bronchoscopy in the endoscopy suite or OR of HUP

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- History of inability to complete bronchoscopy attributable to inadequate sedation


- Requiring more than 2 LPM supplemental oxygen to maintain SaO2 > 90%


- History of allergy to study medications


- Pregnancy


- A history of psychosis


- Any condition deemed likely by the pulmonologist or anesthesiologist to pose a
significant risk due to elevation of blood pressure, including cerebral/aortic
aneurysm, and or ischemic cardiovascular disease


- Bradydysrhythmia deemed significant by the anesthesiologist or pulmonologist


- A diagnosis of significant renal or hepatic impairment

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

SedationAlternative Sedation During Bronchoscopy
NCT01158820
  1. Philadelphia, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
SedationPrecedex Special Investigation (in Pediatric Patients)
NCT04040439
  1. Tokyo,
ALL GENDERS
45 Weeks+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Alternative Sedation During Bronchoscopy
Official Title  ICMJE A Randomized, Placebo-controlled, Concealed Allocation Comparison of Respiratory Depression and Coughing During Bronchoscopy With Dexmedetomidine-ketamine as an Adjunct to Fentanyl-midazolam Sedation
Brief Summary This protocol hopes to determine whether the use of dexmedetomidine-ketamine can reduce the use of standard of care fentanyl-midazolam sedation during bronchoscopy. This may result in less respiratory depression while providing better compliance with the procedure.
Detailed Description All patients enrolled in the study will be undergoing bronchoscopy, which is typically performed with sedation. All procedural sedation carries some risk. Several features of the study may lower the risk of sedation relative to that of conventional sedation. An anesthesiologist will be present throughout the procedure. Continuous monitoring of respiration with RIP will be employed. Administration of sedation will be via a volumetric syringe pump. Benefits specific to dexmedetomidine-ketamine include the lack of respiratory depression and greater hemodynamic stability.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Sedation
Intervention  ICMJE
  • Drug: Dexmedetomidine load
    Dexmedetomidine 1 µg/kg prior to bronchoscopy
    Other Names:
    • Precedex
    • Dexmedetomidine Hydrochloride
  • Drug: Ketamine load
    Ketamine 30 mg bolus prior to bronchoscopy
    Other Names:
    • Ketalar
    • Calypsol
    • Ketamin
    • Ketaminol
    • Ketanest
    • Tekam
    • Vetalar
  • Drug: Midazolam load
    2 mg bolus prior to bronchoscopy
    Other Name: Versed
  • Drug: Fentanyl load
    50 µg bolus prior to bronchoscopy
    Other Names:
    • Abstral
    • Actiq
    • Fentora
    • Onsolis
  • Drug: Dexmedetomidine maintenance
    0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)
    Other Names:
    • Precedex
    • Dexmedetomidine Hydrochloride
  • Drug: Ketamine maintenance
    8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)
    Other Names:
    • Ketalar
    • Calypsol
    • Ketamin
    • Ketaminol
    • Ketanest
    • Tekam
    • Vetalar
  • Drug: Midazolam demand
    0.5 mg demand bolus at discretion of pulmonologist
    Other Name: Versed
  • Drug: Fentanyl demand
    12.5 µg demand bolus at discretion of pulmonologist
    Other Names:
    • Abstral
    • Actiq
    • Fentora
    • Onsolis
  • Drug: Benadryl demand
    25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
    Other Names:
    • Diphenhydramine Hcl
    • Aler-Dryl
    • Banophen
    • Ben Tann
    • Bromanate AF
    • Diphen
    • Diphenadryl
    • Diphenhist
    • Dytan
    • Unisom
    • Sominex
    • Silphen
    • Siladryl
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    midazolam load fentanyl load midazolam demand fentanyl demand benadryl demand
    Interventions:
    • Drug: Midazolam load
    • Drug: Fentanyl load
    • Drug: Midazolam demand
    • Drug: Fentanyl demand
    • Drug: Benadryl demand
  • Active Comparator: dexmedetomidine and ketamine
    dexmedetomidine load ketamine load dexmedetomidine maintenance ketamine maintenance midazolam demand fentanyl demand benadryl demand
    Interventions:
    • Drug: Dexmedetomidine load
    • Drug: Ketamine load
    • Drug: Dexmedetomidine maintenance
    • Drug: Ketamine maintenance
    • Drug: Midazolam demand
    • Drug: Fentanyl demand
    • Drug: Benadryl demand
Publications * Yarmus LB, Akulian JA, Gilbert C, Mathai SC, Sathiyamoorthy S, Sahetya S, Harris K, Gillespie C, Haas A, Feller-Kopman D, Sterman D, Lee HJ. Comparison of moderate versus deep sedation for endobronchial ultrasound transbronchial needle aspiration. Ann Am Thorac Soc. 2013 Apr;10(2):121-6. doi: 10.1513/AnnalsATS.201209-074OC.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 7, 2010)
50
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE May 2012
Actual Primary Completion Date May 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Adults over the age of 18 scheduled for elective flexible bronchoscopy in the endoscopy suite or OR of HUP

Exclusion Criteria:

  • History of inability to complete bronchoscopy attributable to inadequate sedation
  • Requiring more than 2 LPM supplemental oxygen to maintain SaO2 > 90%
  • History of allergy to study medications
  • Pregnancy
  • A history of psychosis
  • Any condition deemed likely by the pulmonologist or anesthesiologist to pose a significant risk due to elevation of blood pressure, including cerebral/aortic aneurysm, and or ischemic cardiovascular disease
  • Bradydysrhythmia deemed significant by the anesthesiologist or pulmonologist
  • A diagnosis of significant renal or hepatic impairment
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01158820
Other Study ID Numbers  ICMJE 810981
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University of Pennsylvania
Study Sponsor  ICMJE University of Pennsylvania
Collaborators  ICMJE Hospira, now a wholly owned subsidiary of Pfizer
Investigators  ICMJE
Principal Investigator:Jeff E Mandel, MD MSUniversity of Pennsylvania
PRS Account University of Pennsylvania
Verification Date February 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP